HOWL (Werewolf Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by HOWL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-08 | LUKE EVNIN | Director | Sell | — | — |
| 2026-06-29 | LUKE EVNIN | Director | Sell | — | — |
| 2026-06-22 | RA CAPITAL MANAGEMENT, L.P. | 10%+ Owner | Sell | — | — |
| 2026-06-16 | Rajeev M. Shah | 10%+ Owner | Sell | — | — |
| 2026-06-11 | Peter Kolchinsky | 10%+ Owner | Sell | — | — |
| 2026-06-10 | LUKE EVNIN | Director | Sell | — | — |
| 2026-06-08 | LUKE EVNIN | Director | Sell | — | — |
| 2026-06-03 | LUKE EVNIN | Director | Sell | — | — |
| 2026-05-29 | LUKE EVNIN | Director | Sell | — | — |
| 2026-05-26 | LUKE EVNIN | Director | Sell | — | — |
| 2026-05-20 | LUKE EVNIN | Director | Sell | — | — |
| 2026-05-13 | LUKE EVNIN | Director | Sell | — | — |
| 2026-05-12 | LUKE EVNIN | Director | Sell | — | — |
| 2026-05-12 | Peter Kolchinsky | 10%+ Owner | Sell | — | — |
| 2026-05-07 | LUKE EVNIN | Director | Sell | — | — |
| 2026-05-04 | LUKE EVNIN | Director | Sell | — | — |
| 2026-04-29 | LUKE EVNIN | Director | Sell | — | — |
| 2026-01-20 | LUKE EVNIN | Director | Sell | — | — |
| 2026-01-15 | LUKE EVNIN | Director | Sell | — | — |
| 2026-01-12 | LUKE EVNIN | Director | Sell | — | — |
| 2026-01-07 | LUKE EVNIN | Director | Sell | — | — |
| 2026-01-02 | LUKE EVNIN | Director | Sell | — | — |
| 2025-12-29 | LUKE EVNIN | Director | Sell | — | — |
| 2025-12-17 | LUKE EVNIN | Director | Sell | — | — |
| 2025-12-12 | LUKE EVNIN | Director | Sell | — | — |
| 2025-12-09 | LUKE EVNIN | Director | Sell | — | — |
| 2025-12-04 | LUKE EVNIN | Director | Sell | — | — |
| 2025-12-04 | MPM BioVentures 2014, L.P. | — | Sell | — | — |
| 2025-12-04 | MPM ASSET MANAGEMENT LLC | — | Sell | — | — |
| 2025-12-01 | LUKE EVNIN | Director | Sell | — | — |
| 2025-12-01 | MPM ASSET MANAGEMENT LLC | 10%+ Owner | Sell | — | — |
| 2025-12-01 | MPM Asset Management Investors BV2014 LLC | 10%+ Owner | Sell | — | — |
| 2025-11-25 | LUKE EVNIN | Director | Sell | — | — |
| 2025-11-25 | MPM BioVentures 2014 LLC | 10%+ Owner | Sell | — | — |
| 2025-11-25 | Oncology Impact Fund (Cayman) Management L.P. | 10%+ Owner | Sell | — | — |
| 2025-11-20 | MPM BioVentures 2014 LLC | 10%+ Owner | Sell | — | — |
| 2025-11-20 | Oncology Impact Fund (Cayman) Management L.P. | 10%+ Owner | Sell | — | — |
| 2025-11-20 | LUKE EVNIN | Director | Sell | — | — |
| 2025-11-17 | LUKE EVNIN | Director | Sell | — | — |
| 2025-11-17 | MPM Oncology Innovations Fund GP LLC | 10%+ Owner | Sell | — | — |
| 2025-11-17 | MPM Asset Management Investors BV2014 LLC | 10%+ Owner | Sell | — | — |
| 2025-11-12 | MPM BioVentures 2014 (B), L.P. | 10%+ Owner | Sell | — | — |
| 2025-11-12 | LUKE EVNIN | Director | Sell | — | — |
| 2025-11-12 | MPM ASSET MANAGEMENT LLC | 10%+ Owner | Sell | — | — |
| 2025-11-06 | LUKE EVNIN | Director | Sell | — | — |
| 2025-11-06 | MPM BioVentures 2014 GP LLC | 10%+ Owner | Sell | — | — |
| 2025-11-06 | Oncology Impact Fund (Cayman) Management L.P. | 10%+ Owner | Sell | — | — |
| 2025-11-03 | LUKE EVNIN | Director | Sell | — | — |
| 2025-11-03 | MPM BioVentures 2014 LLC | 10%+ Owner | Sell | — | — |
| 2025-11-03 | ANSBERT GADICKE | 10%+ Owner | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 6,718,670 | — |
| — | 10%+ Owner | 6,147,610 | — |
| — | 10%+ Owner | 5,904,720 | — |
| — | 10%+ Owner | 5,731,860 | — |
| — | Director | 5,701,056 | — |
| — | 10%+ Owner | 5,538,600 | — |
| — | 10%+ Owner | 5,257,105 | — |
| — | 10%+ Owner | 5,125,770 | — |
| — | 10%+ Owner | 5,076,685 | — |
| — | 10%+ Owner | 5,044,760 | — |
| — | — | 4,867,341 | — |
| — | 10%+ Owner | 4,784,111 | — |
| — | Director | 1,756,409 | — |
| — | 10%+ Owner | 1,752,787 | — |
| — | Director | 1,646,634 | — |
| — | 10%+ Owner | 1,427,082 | — |
| — | 10%+ Owner | 1,318,311 | — |
| — | 10%+ Owner | 1,235,917 | — |
| — | 10%+ Owner | 1,097,756 | — |
| — | 10%+ Owner | 787,997 | — |
| — | 10%+ Owner | 625,995 | — |
| — | Director | 341,353 | — |
| — | Director | 303,719 | — |
| — | Chief Scientific Officer | 164,888 | — |
| — | Chief Operating Officer | 136,259 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the HOWL quote page; the site-wide leaderboard is on the insider transactions hub.